Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 5Stomach Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Neoplasms 2Melanoma 2Advanced Pancreatic Cancer 2Thoracic Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Lung 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Second Line Treatment of Gastric Cancer 1Sarcoma 1Resectable Biliary Tract Cancer 1Pathologic Complete Response 1Pancreatic Adenocarcinoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-Invasive Bladder Carcinoma 1Lung Diseases 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Resectable Biliary Tract Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡